濾胞性リンパ腫および辺縁帯リンパ腫の参加者を対象に、オドロネクタマブとレナリドミドの併用が安全で、リツキシマブとレナリドミドの併用よりも効果があるかどうかを調べる試験 (OLYMPIA-5)
濾胞性の再発/難治性参加者を対象に、抗CD20 x 抗CD3二重特異性抗体であるオドロネクタマブ(REGN1979)とレナリドミドの併用療法とリツキシマブとレナリドミド療法の併用療法の有効性と安全性を比較する第3相非盲検ランダム化試験リンパ腫および辺縁帯リンパ腫 (OLYMPIA-5)
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL).
This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).
The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before.
The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug in combination with lenalidomide
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Clinical Trials Administrator
- 電話番号:844-734-6643
- メール:clinicaltrials@regeneron.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- 募集
- David Geffen School of Medicine at UCLA
-
-
Florida
-
Plantation、Florida、アメリカ、33322
- 募集
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Indiana University and Comprehensive Cancer Center
-
-
Mississippi
-
Hattiesburg、Mississippi、アメリカ、39401
- 募集
- Hattiesburg Clinic
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- 募集
- Dartmouth Cancer Center
-
-
New York
-
Stony Brook、New York、アメリカ、11794
- 募集
- Stony Brook University Hospital
-
Westbury、New York、アメリカ、11590
- 引きこもった
- Clinical Research Alliance Inc
-
-
North Carolina
-
Greenville、North Carolina、アメリカ、27834
- 募集
- East Carolina University
-
-
Wisconsin
-
Waukesha、Wisconsin、アメリカ、53188
- 募集
- Prohealth Care Inc
-
-
-
-
-
Great Yarmouth、イギリス、NR31 6LA
- 募集
- James Paget University Hospitals NHS Foundation Trust
-
Romford、イギリス、RM7 0AG
- 募集
- Barking, Havering and Redbridge University Hospitals NHS Trust
-
Warwick、イギリス、CV34 5BW
- 募集
- South Warwickshire NHS Foundation Trust
-
-
Cornwall
-
Truro、Cornwall、イギリス、TR1 3LJ
- 募集
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
Devon
-
Plymouth、Devon、イギリス、PL6 8DH
- 募集
- Derriford Hospital and the Royal Eye Infirmary
-
-
Dorset
-
Bournemouth、Dorset、イギリス、BH7 7DW
- 募集
- University Hospitals Dorset
-
-
Hampshire
-
Salisbury、Hampshire、イギリス、SP6 2ND
- 募集
- Salisbury Foundation Trust
-
-
Middlesex
-
Uxbridge、Middlesex、イギリス、UB8 3NN
- 募集
- The Hillingdon Hospital
-
-
Surrey
-
Sutton、Surrey、イギリス、SM2 5PT
- 募集
- The Royal Marsden NHS Foundation Trust
-
-
-
-
-
Ashdod、イスラエル、7747629
- 募集
- Assuta Ashdod Medical Center
-
Jerusalem、イスラエル、91200
- 募集
- Hadassah Medical Center
-
Nahariya、イスラエル、2210001
- 募集
- Galilee Medical Center
-
Petah Tikva、イスラエル、49100
- 募集
- Rabin Medical Center
-
Ramat Gan、イスラエル、5265601
- 募集
- Chaim Sheba Medical Center
-
Tel Aviv、イスラエル、64239
- 募集
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv、イスラエル、6971028
- 募集
- Assuta Medical Centers
-
-
-
-
-
Bologna、イタリア、40138
- 募集
- University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale
-
Brescia、イタリア、25123
- 募集
- Azienda Ospedaliera Spedali Civili di Brescia
-
Milan、イタリア、20141
- 募集
- Istituto Europeo di Oncologia
-
Milan、イタリア、20162
- 募集
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan、イタリア、20122
- 募集
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena、イタリア、41124
- 募集
- A.O.U. di Modena
-
Naples、イタリア、80131
- 募集
- Federico II University
-
Novara、イタリア、28100
- 募集
- AOU Maggiore della Carita
-
Pavia、イタリア、27100
- 募集
- Fondazione IRCCS Policlinico San Matteo
-
Perugia、イタリア、06132
- 募集
- Azienda Ospedaliera di Perugia
-
Ravenna、イタリア、48121
- 募集
- Ospedale Santa Maria delle Croci
-
Udine、イタリア、33100
- 募集
- Santa Maria della Misericordia
-
-
Forli-Cesena
-
Meldola、Forli-Cesena、イタリア、47014
- 募集
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Genova
-
Genoa、Genova、イタリア、16132
- 募集
- Ospedale Policlinico San Martino IRCCS
-
-
Monza E Brianza
-
Monza、Monza E Brianza、イタリア、20900
- 募集
- S Gerardo Hospital
-
-
Piedmont
-
Turin、Piedmont、イタリア、10126
- 募集
- A.O.U. Citta della Salute e della Scienza di Torino
-
-
Pordenone
-
Aviano、Pordenone、イタリア、33081
- 募集
- Centro Di Riferimento Oncologico (CRO), Aviano, National Cancer Institute
-
-
Torino
-
Candiolo、Torino、イタリア、10060
- 募集
- Candiolo Cancer Institute, FPO, IRCCS
-
-
-
-
New South Wales
-
Liverpool、New South Wales、オーストラリア、2170
- 募集
- Liverpool Hospital
-
Waratah、New South Wales、オーストラリア、2298
- 募集
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa、Queensland、オーストラリア、4217
- 募集
- Pindara Private Hospital
-
-
Tasmania
-
Hobart、Tasmania、オーストラリア、7000
- 募集
- Royal Hobart Hospital
-
-
Victoria
-
East Melbourne、Victoria、オーストラリア、3121
- 募集
- Epworth Freemasons
-
-
-
-
-
Vienna、オーストリア、1090
- 募集
- Medical University Vienna
-
Wels、オーストリア、4600
- 募集
- Klinikum Wels-Grieskirchen
-
-
Osterreich
-
Linz、Osterreich、オーストリア、4020
- 募集
- Ordensklinikum Linz
-
-
Upper Austria
-
Linz、Upper Austria、オーストリア、4020
- 募集
- Kepler University Hospital
-
-
-
-
-
Barcelona、スペイン、08036
- 募集
- Hospital Clinic de Barcelona
-
Barcelona、スペイン、08035
- 募集
- University Hospital Vall d'Hebron
-
Barcelona、スペイン、08041
- 募集
- Hospital de la Santa Creu i Sant Pau
-
Granada、スペイン、18014
- 募集
- Hospital Virgen De Las Nieves De Granada
-
Madrid、スペイン、28034
- 募集
- Hospital Universitario Ramon y Cajal
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro
-
Madrid、スペイン、28040
- 募集
- Fundacion Jimenez Diaz University Hospital
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario12 de Octubre
-
Salamanca、スペイン、37007
- 募集
- Hospital Universitario de Salamanca
-
Seville、スペイン、41013
- 募集
- University Hospital Virgen del Rocio
-
Valencia、スペイン、46017
- 募集
- University Hospital Doctor Peset
-
Valencia、スペイン、46009
- 募集
- Instituto Valenciano de Oncologia
-
-
A Coruna
-
Santiago de Compostela、A Coruna、スペイン、15706
- 募集
- University Hospital of Santiago de Compostela
-
-
Balearic Islands
-
Palma、Balearic Islands、スペイン、07120
- 募集
- Son Espases University Hospital
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08908
- 募集
- Institut Catala d'Oncologia
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- 募集
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- 募集
- Hospital Universitario Quironsalud Madrid
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、スペイン、33011
- 募集
- Hospital Universitario Central de Asturias
-
-
-
-
-
Bangkok、タイ、10700
- 募集
- Sriraj Hospital
-
Chiang Mai、タイ、50200
- 募集
- Chiang Mai University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok、Krung Thep Maha Nakhon [Bangko]、タイ、10330
- 募集
- Chulalongkorn University
-
-
-
-
-
Brno、チェコ、62500
- 募集
- Fakultni Nemocnice Brno
-
Prague、チェコ、10034
- 募集
- University Hospital Kralovske Vinohrady
-
Prague、チェコ、12808
- 募集
- Vseobecna Fakultni Nemocnice V Praze
-
-
East Bohemia
-
Hradec Králové、East Bohemia、チェコ、50005
- 募集
- University Hospital Hradec Kralove
-
-
-
-
-
Istanbul、トルコ(Türkiye)、34093
- 募集
- Istanbul University, Istanbul Medical Faculty
-
Izmir、トルコ(Türkiye)、35340
- 募集
- Dokuz Eylul University
-
Izmir、トルコ(Türkiye)、35100
- 募集
- Ege University
-
Sakarya、トルコ(Türkiye)、54290
- 募集
- Sakarya University Medical Faculty
-
Samsun、トルコ(Türkiye)、55270
- 募集
- Ondokuz Mayıs University
-
Zonguldak、トルコ(Türkiye)、67600
- 募集
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak、Ankara、トルコ(Türkiye)、06620
- 募集
- Ankara University Faculty of Medicine
-
Yenimahalle、Ankara、トルコ(Türkiye)、06200
- 募集
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara、Central Anatolia、トルコ(Türkiye)、06100
- 募集
- Gazi University
-
-
Mersin
-
Mezitli、Mersin、トルコ(Türkiye)、33200
- 募集
- VM Medical Park Mersin Hospital
-
-
Suleymanpasa
-
Tekirdağ、Suleymanpasa、トルコ(Türkiye)、59100
- 募集
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Halle、ドイツ、6120
- 募集
- University Hospital Halle Saale
-
Kiel、ドイツ、24116
- 募集
- Stadtisches Krankenhaus Kiel
-
Neuss、ドイツ、41462
- 募集
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
Baden-Wurttemberg
-
Mutlangen、Baden-Wurttemberg、ドイツ、73557
- 募集
- Stauferklinikum
-
Stuttgart、Baden-Wurttemberg、ドイツ、70376
- 募集
- Robert-Bosch-Krankenhaus
-
-
Bavaria
-
Munich、Bavaria、ドイツ、80337
- 募集
- LMU Klinikum
-
Munich、Bavaria、ドイツ、81675
- 募集
- TUM Fakultat fur Medizin - Klinikum Rechts der Isar
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、15236
- 募集
- Clinic Frankfurt (Oder)
-
-
North Rhine-Westphalia
-
Essen、North Rhine-Westphalia、ドイツ、45122
- 募集
- University Hospital Essen
-
-
Rhineland-Palatinate
-
Mainz、Rhineland-Palatinate、ドイツ、55131
- 募集
- Universitatsmedizin der Johannes-Gutenberg Universitat Mainz
-
-
-
-
-
Avignon、フランス、84000
- 募集
- Centre Hospitalier d'Avignon
-
Montpellier、フランス、34290
- 募集
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris、フランス、75010
- 募集
- Hopital Saint Louis
-
Paris、フランス、75571
- 募集
- Assistance Publique-Hopitaux de Paris (AP-HP)
-
Saint-Cloud、フランス、92210
- 募集
- Institut Curie
-
-
Bouches Du Rhone
-
Marseille、Bouches Du Rhone、フランス、13009
- 募集
- Institut Paoli-Calmettes
-
-
Brittany Region
-
Rennes、Brittany Region、フランス、35033
- 募集
- CHU de Rennes
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、フランス、37044
- 募集
- Centre Hospitalier Regional Universitaire de Tours
-
-
Gironde
-
Bordeaux、Gironde、フランス、33077
- 募集
- Polyclinique Bordeaux Nord Aquitaine
-
Pessac、Gironde、フランス、33600
- 募集
- Centre Francois Magendie
-
-
Nord
-
Lille、Nord、フランス、5900
- 募集
- Hopital Saint Vincent-de-Paul
-
-
Normandy
-
Rouen、Normandy、フランス、76038
- 募集
- Centre Henri Becquerel
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、フランス、44093
- 募集
- Nantes University Hospital
-
-
Savoie
-
Chambéry、Savoie、フランス、73000
- 募集
- Centre Hospitalier Metropole Savoie
-
-
Île-de-France Region
-
Argenteuil、Île-de-France Region、フランス、95100
- 募集
- Hopital Victor Dupouy Argenteuil
-
Bobigny、Île-de-France Region、フランス、93000
- 募集
- Avicenne Hospital
-
Villejuif、Île-de-France Region、フランス、94800
- 募集
- Gustave Roussy
-
-
-
-
-
Rio de Janeiro、ブラジル、20231050
- 募集
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo、ブラジル、01321000
- 募集
- A Beneficencia Portuguesa de Sao Paulo, Oncology House
-
São Paulo、ブラジル、01308-050
- 募集
- Hospital Sirio Libanes
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、40285-000
- 募集
- Hospital Sao Rafael
-
-
Federal District
-
Brasília、Federal District、ブラジル、70200-730
- 募集
- Hospital Sirio Libanes Brasilia
-
-
Paraná
-
Cascavel、Paraná、ブラジル、85806-300
- 募集
- Uopeccan Hospital do Cancer de Cascavel
-
Curitiba、Paraná、ブラジル、81520-060
- 募集
- Hospital Erasto Gaertner
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
- 募集
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre、Rio Grande do Sul、ブラジル、90110-270
- 募集
- Centro Gaucho Integrado
-
-
São Paulo
-
Jaú、São Paulo、ブラジル、17210-080
- 募集
- Amaral Carvalho Hospital
-
-
-
-
-
Antwerp、ベルギー、2060
- 募集
- Ziekenhuis Netwerk Antwerpen Stuivenberg
-
Brussels、ベルギー、1000
- 募集
- Institut Jules Bordet
-
-
Namur
-
Yvoir、Namur、ベルギー、5530
- 募集
- Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- 募集
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
-
West-Vlaanderen
-
Roeselare、West-Vlaanderen、ベルギー、8800
- 募集
- Algemeen Ziekenhuis AZ Delta
-
-
-
-
-
Bydgoszcz、ポーランド、85-168
- 引きこもった
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Katowice、ポーランド、40-519
- 募集
- Pratia Onkologia Katowice
-
Lodz、ポーランド、93-513
- 募集
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Warsaw、ポーランド、02-781
- 募集
- Narodowy Instytut Onkologii
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、ポーランド、85-048
- 募集
- In-Vivo Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Wałbrzych、Lower Silesian Voivodeship、ポーランド、58-309
- 募集
- Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu
-
Wroclaw、Lower Silesian Voivodeship、ポーランド、50-367
- 募集
- Uniwersytecki Szpital Kliniczny
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、ポーランド、20-090
- 募集
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Centrum Innowacyjnych Terapii
-
-
Malopolska
-
Krakow、Malopolska、ポーランド、30-510
- 募集
- Pratia MCM Krakow
-
-
Pomeranian Voivodeship
-
Gdansk、Pomeranian Voivodeship、ポーランド、80-952
- 募集
- Uniwersyteckie Centrum Kliniczne
-
-
Wielkopolska
-
Poznan、Wielkopolska、ポーランド、60185
- 完了
- Pratia Poznan Medical Center
-
Skorzewo、Wielkopolska、ポーランド、60185
- 募集
- Aidport Sp. z o.o.
-
-
-
-
Johor
-
Johor Bahru、Johor、マレーシア、80100
- 募集
- Hospital Sultanah Aminah Jhor Bahru
-
-
Negeri / Wilayah Persekutuan
-
Kuala Lumpur、Negeri / Wilayah Persekutuan、マレーシア、50603
- 募集
- University of Malaya Medical Centre
-
-
Sabah
-
Kota Kinabalu、Sabah、マレーシア、88586
- 募集
- Hospital Queen Elizabeth
-
-
Selangor
-
Ampang、Selangor、マレーシア、68000
- 募集
- Hospital Ampang
-
Subang Jaya、Selangor、マレーシア、47500
- 募集
- Subang Jaya Medical Center
-
-
-
-
-
Changhua、台湾、500-06
- 募集
- Changhua Christian Hospital
-
Changhua、台湾、50008
- 募集
- Show Chwan Memorial Hospital
-
Kaohsiung City、台湾、83301
- 募集
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、80756
- 募集
- Kaohsiung Medical University Hospital
-
New Taipei City、台湾、23561
- 募集
- Taipei Medical University - Shuang Ho Hospital
-
Tainan、台湾、701
- 募集
- National Cheng Kung University Hospital
-
Taipei、台湾、10002
- 募集
- National Taiwan University Hospital
-
Taipei、台湾、11217
- 募集
- Taipei Veterans General Hospital
-
Taipei、台湾、11490
- 募集
- Tri-Service General Hospital
-
Taipei、台湾、116
- 募集
- Taipei Municipal Wan Fang Hospital
-
Taoyuan City、台湾、333
- 募集
- Chang Gung Memorial Hospital
-
-
Chiayi County
-
Buzi、Chiayi County、台湾、613
- 募集
- Chang Gung Medical Foundation Chia Yi Branch
-
-
-
-
-
Busan、韓国、49241
- 募集
- Pusan National University Hospital
-
Busan、韓国、47392
- 募集
- Inje University Busan Paik Hospital
-
Daegu、韓国、42415
- 引きこもった
- Yeyungnam University Medical Center
-
Seoul、韓国、05505
- 募集
- Asan Medical Center
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center
-
Seoul、韓国、3080
- 募集
- Seoul National University Hospital
-
Seoul、韓国、07345
- 募集
- Yeouido St. Marys Hospital
-
Seoul、韓国、03722
- 募集
- Yonsei University Health System
-
Seoul、韓国、137-701
- 募集
- Seoul St Marys Hospital
-
Ulsan、韓国、44033
- 募集
- Ulsan University Hospital
-
-
Gyeonggi-do
-
Suwon、Gyeonggi-do、韓国、16247
- 募集
- St. Vincents Hospital - The Catholic University of Korea
-
-
Jeollabuk
-
Jeonju、Jeollabuk、韓国、54907
- 募集
- Jeonbuk National University Hospital
-
-
Namdong-Gu
-
Incheon、Namdong-Gu、韓国、21565
- 募集
- Gachon University Gil Medical Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
-
Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
-
Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody, and participant should meet indication for treatment, as described in the protocol.
-
Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography [CT], or Magnetic Resonance Imaging [MRI] imaging, as described in the protocol.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate hematologic and organ function, as described in the protocol.
-
All study participants must:
- Have an understanding that lenalidomide could have a potential teratogenic risk.
- Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
- Agree not to share study medication with another person.
- Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.
Key Exclusion Criteria:
- Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
- Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
- History of or current relevant CNS pathology, as described in the protocol.
- A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
- Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
- Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.
- Active infection as defined in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Odronextamab+Lenalidomide
In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide. In part 2, 1:1 randomized participants with R/R FL and MZL, will receive odronextamab in combination with lenalidomide. |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Rituximab+Lenalidomide
In part 2 only, 1:1 randomized participants with R/R FL and ML, will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy. |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide
時間枠:Up to 35 days
|
Part 1 |
Up to 35 days
|
|
Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide
時間枠:Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide
時間枠:Up to 2 years
|
Part 1 |
Up to 2 years
|
|
Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time To Next anti-lymphoma Treatment (TTNT)
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Odronextamab concentrations in serum
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of Anti-Drug Antibodies (ADA) to odronextamab
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Magnitude of ADAs to odronextamab
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best Overall Response (BOR) as assessed by investigator review
時間枠:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Duration of Response (DOR) as assessed by investigator review
時間枠:Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
PFS as assessed by investigator review
時間枠:Up to 5 years
|
Part 1 and Part 2 |
Up to 5 years
|
|
Complete Response (CR) as assessed by ICR
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
BOR as assessed by ICR
時間枠:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Event Free Survival (EFS) as assessed by ICR
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator review
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by ICR
時間枠:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Incidence of TEAEs for odronextamab in combination with lenalidomide versus R2
時間枠:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs for odronextamab in combination with lenalidomide versus R2
時間枠:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Overall change in Patient Reported Outcomes (PROs) as measured by scores of European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQC30)
時間枠:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a Global Health Status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and GHS/QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)
時間枠:Up to 5 years
|
Part 2 The FACT-Lym Lymphoma Subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Overall change in PROs as measured by scores of EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)
時間枠:Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ Visual Analogue Scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Severity (PGIS)
時間枠:Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change from first assessment in Patient Global Impression on Change (PGIC)
時間枠:Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
Change from first assessment in the Global Population item 5 (GP5) items of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire
時間枠:Up to 5 years
|
Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 新生物
- 疾患の属性
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫、B細胞
- リンパ腫
- 病理学的状態、徴候および症状
- ヘミックおよびリンパ疾患
- 再発
- リンパ腫、濾胞性
- リンパ腫、B細胞、辺縁帯
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- ピペリジン
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 抗体、モノクローナル、マウス由来
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- リツキシマブ
その他の研究ID番号
その他の研究ID番号
- R1979-ONC-22102
- 2022-503092-28-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共有時間枠
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。